Welcome to the Melanoma meeting

Preliminary programme

Melanoma: From Basic Science to Clinical Applications – 2015.
Preliminary program
The meeting will take place in the Kaldalón lecture hall in Harpa Concert Hall and Conference Center
Reykjavik, Iceland



Wednesday, June 24th

 12:00 – 14:00      Arrival and Registration
14:00 – 14:15      Welcome address and Introduction

 14:15 – 16:10      Session 1a: Melanocyte and melanoma development
                             Chaired by Eirikur STEINGRIMSSON.

 14:15 – 14:55  -  Keynote lecture
           Kari STEFANSSON, Decode Genetics, Reykjavík, Iceland
           Genetics of Common Complex Traits
14:55 – 15:20
            Glenn MERLINO, National Cancer Institute, Bethesda, USA
             Modeling the genesis, progression and treatment of human melanoma in 
             the mouse
15:20 – 15:45
             Martin MC MAHON, University of California San Francisco, USA
             Using Genetically Engineered Mouse Models To Develop Pathway-Targeted
             Therapies For BRAF-Mutated Melanoma
15:45 – 16:10
             Colin GODING, Ludwig Institute for Cancer Research, Oxford, UK
             A novel mode of MITF regulation drives invasiveness

 16:10 – 17:10      Poster session #1 and Coffee break

 Wednesday, June 24th

 17:10 – 18:45      Session 1b: Melanocyte and melanoma development
Chaired by Lionel LARUE

 17:10 – 17:35
              Angelo CICALESE, IFOM-IEO, Milan, Italy
              Challenging new epigenetic vulnerabilities in human metastatic melanomas:
              KMT2D at a crossroad between NRAS and BRAF
17:35 – 17:50
              Mike MILBURN, Metabolon, North Carolina, USA
              Applicability of global biochemical profiling to understand cancer 
              metabolomic signatures
17:50 – 18:05
             Hannah SEBERG, University of Iowa, Iowa, USA
             TFAP2A drives melanocyte gene expression in parallel with MITF
18:05 – 18:20
             Sigurđur GUĐMUNDSSON, University of Iceland, Reykavík, Iceland
             The nuclear localization and stability of the MITF transcription factor
18:20 – 18:45
            Malin PEDERSEN, Cancer Research UK Manchester Institute, UK
             From UV-driven melanomagenesis to novel therapeutic strategies

18:45 – 20:00      Reception with all participants. Finger food and drinks 

 Thursday, June 25th

 09:00 – 11:50    
                    Session 2: Gene regulation in melanocytes and melanoma     
                   Chaired by Caroline ROBERT.
09:00 – 09:25
            Anja BOSSERHOFF, Friedrich-Alexander University, Germany
             Learning from embryogenesis: molecular changes in melanoma development
09:25 – 09:50
             Robert BALLOTTI, INSERM, Nice, France
             Melanoma initiating cells, senescence and resistance: MITF takes the central
09:50 – 10:15
             Svenja MEIERJOHANN, University of Würzburg, Germany
             In vitro evidence for senescent multinucleated melanocytes as a source for 
             melanoma initiating cells

10:15 – 10:55      Coffee break

Thursday, June 25th

                   Session 2: Gene regulation in melanocytes and melanoma
Chaired by Caroline ROBERT.
10:55 – 11:10
             Irwin DAVIDSON, IGBMC, Illkirch, France
             Epigenetic regulation of melanoma gene expression by MITF and chromatin
             remodelling complexes
11:10 – 11:25
             Jean-Philippe LAMBERT, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada
             Functional proteomics characterization of epigenetics regulators involved in melanoma
11:25 – 11:50
             Simon N. STACEY, Decode Genetics, Reykjavik, Iceland
             Association Studies of Skin Cancer based on Whole Genome Sequencing

12:00 – 13:30      Luncheon clinical update and current needs.
Chaired by Rene GONZALEZ and Ze'ev RONAI.
                            Room FLOI

12:00 – 12:20
             Caroline ROBERT, Gustave-Roussy, Villejuif, France
12:20 – 12:40
             Karl LEWIS, University of Colorado, Denver, USA
             The current clinical status of BRAF-targeted therapy in melanoma
12:40– 13:00
            Boris BASTIAN, University of California San Francisco, USA
            Mediators of oncogenic effects of mutant GNAQ in uveal melanoma
13:00 - 13:30
           Discussion all participants

13:30 – 15:00      Poster session #2
Thursday, June 25th

 15:00– 17:35       Session 3: Cell biology to Pathology.
                            Chaired by Thorunn RAFNAR.
15:00 - 15:25
            Chiara VARDABASSO, Icahn Schoole of Medicine, New York, US
             Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma
15:25 - 15:50
             Victoria SANZ MORENO, King's College, London, UK
             Using multidisciplinary approaches to understand the role of cytoskeletal dynamics in
15:50 - 16:15
            Marisol SOENGAS, CNIO, Madrid, Spain
            Therapeutic targeting of lymphoid and myeloid immune compartments in aggressive 
            melanomas by dsRNA-based viral nanomimics

16:15 – 16:40      Coffee break

16:40 - 16:55
            Emily CLEMENT, IPBS, Toulouse, France
            Adipocyte exosomes as actors in melanoma progression
16:55 - 17:10
            Karin OLLINGER, Linkoping University, Linkoping, Sweden
            The relationship between UV induced lysosomal exocytosis and melanosome transfer in
17:10 - 17:35
            Stephan VAGNER, Institut Curie, Orsay, France
            Messenger RNA translation and resistance to anti-cancer targeted therapy

17:35 – 19:00      Beer & Poster session #3

19:30 – 22:30      Gala dinner

Friday, June 26th

09:30 – 12:10      Session 4: Pathology to genomics
Chaired by Colin GODING.
09:30 - 09:55
            Daniel PEEPER, Netherlands Cancer Institute, Amsterdam, NL
            Systematic genetic perturbations to reveal melanoma dependencies in vitro and in vivo
09:55 - 10:20
            Leon VAN KAMPEN, McGill University, Montreal, Canada
            The plasticity of chromatin architecture in melanoma
10:20 - 10:35
            Nicolas DUMAZ, Hopital Saint-Louis, Paris, France
            Hypoxia and MITF regulate oncogenic properties of KIT in melanocytes

10:35 – 11:05      Coffee break

11:05 - 11:20
            Petra WASTER, Linkoping University, Linkoping, Sweden
            Ultraviolet exposure of melanoma cells induces fibroblast activation protein-a (FAP-a) in
            dermal fibroblasts facilitating melanoma invasion
11:20 - 11:45
            Yardena SAMUELS, Weizmann Institute, Rehovot, Israel
            Genetic and Functional Discovery of Melanoma Targets and their Integration into Melanoma
11:45 - 12:10
            Gunhild Mari MAELANDSMO, Oslo University Hospital, Oslo, NO
            Tumor-stroma interactions, metabolic reprogramming and drug responses in melanoma

 12:10 – 13:40      Lunch & Poster session #4

Friday, June 26th

13:40 – 16:15      Session 5: Clinical advances - future steps.
Chaired by Karl LEWIS.
13:40 - 14:05
            Robert ANDTBACKA, Huntsman Cancer Institute, Salt Lake City, USA
14:05 - 14:20
            Marie-Dominique GALIBERT, University of Rennes, Rennes, France
            Restoring microRNA activity to reset a potent anti-melanoma mechanism: a new therapeutic
14:20 - 14:35
            Andrew APLIN, Thomas Jefferson University, Philadelphia, USA
            Reporting on the ERK1/2 and CDK4/6 pathways in vivo

14:35 – 15:05      Coffee break

15:05 - 15:20
            Georg BRUNNER, NeraCare GmbH, Germany
            Validation of a predictive risk score in FFPE primary melanomas difficult to classify by AJCC
15:20 - 15:45
            Thomas GAJEWSKI, University of Chicago, Chicago, USA
            Molecular mechanisms of the T cell-inflamed tumor microenvironment: Implications for
            melanoma immunotherapy
15:45 - 16:15  -  Keynote lecture
            Keith FLAHERTY, Harvard Medical School, Boston, USA
            Optimizing and building on MAP kinase pathway blockade

16:15 – 16:25      Conclusion and end of the meeting.

16:25 – 16:55      Refreshments and trip to Blue Lagoon







cpreykjavik@cpreykjavik.is  | tel +354 510 3900